Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells Injection in ALS
NCT02116634Phase 2Withdrawn
- Sponsor
- Al Zahra Hospital
- Start
- May 2015
- Primary completion
- May 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mesenchymal stem cells in amyotrophic lateral sclerosis (ALS), sponsored by Al Zahra Hospital. Primary endpoint: Effect of Intrathecal injection of autologous mesenchymal stem cells in improving the symptoms of ALS at 24 months. Planned start May 2015; status: withdrawn.
02
Drugs
mesenchymal stem cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02116634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116634.